Search

News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?

The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?

Source: Multiple Sclerosis 17. 12. 2020

News Position of Parenteral Therapy in Patients with Severe COVID-19 Disease

Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency requiring non-invasive or invasive pulmonary ventilation. Intensive care therapy is associated with a high risk of severe malnutrition. According to current recommendations by the European Society for Clinical Nutrition and Metabolism, parenteral therapy plays an important role in the nutrition of patients.

Source: Parenteral Nutrition 30. 3. 2021

News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients

The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.

Source: Parenteral Nutrition 16. 9. 2020

News Dupilumab in the Treatment of Severe Asthma in Real-World Practice

A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 20. 10. 2020

News Modern Techniques and MRI Markers in Multiple Sclerosis Imaging or How to Increase Specificity and Sensitivity of Examinations

MRI is a key component in the diagnosis of multiple sclerosis (MS). However, despite significant progress in imaging methods, specificity is still not optimal. The current trend is to refine and clearly define MRI criteria for diagnosing multiple sclerosis and distinguishing it from MS-mimicking white matter lesions.

Source: Multiple Sclerosis 26. 5. 2020

News Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction

Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.

Source: Chronic Heart Failure and Lipidology 7. 9. 2021

News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).

Source: Hematologic Malignancies 27. 4. 2022

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs –⁠ sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) –⁠ in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.

Source: Cardiovascular Continuum 18. 11. 2021

News Diosmin –⁠ Still an Important Modality in the Treatment of Venous Insufficiency

Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately, it remains without causal treatment. In the recommended therapeutic procedures, especially in the initial stages, compression treatment supplemented with pharmacotherapy plays a key role. This includes the administration of medicinal products containing micronized diosmin. The following text summarizes basic findings about its properties that predispose it to clinical use.

Source: Venous Insufficiency 3. 1. 2020

News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis

Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.

Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?

Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.

Source: Arthritis 9. 7. 2020

News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?

In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.

Source: Arthritis 21. 4. 2020

News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice

At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.

Source: Intestinal Inflammations 20. 9. 2023

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.

Source: Thromboprophylaxis 28. 11. 2023

News Safety of Metamizole in Adult Patients –⁠ Meta-analysis of 79 Studies

Metamizole is a non-opioid analgesic with antipyretic and spasmolytic effects that has been used for over 100 years. It is approved for the treatment of children and adults in various dosage forms. German authors conducted a systematic literature review and meta-analysis of clinical studies to evaluate its safety compared to placebo and other analgesics in adult patients.

Source: Analgesia 30. 5. 2024